Hem Onc Presentation
Transcript of Hem Onc Presentation
-
7/31/2019 Hem Onc Presentation
1/56
-
7/31/2019 Hem Onc Presentation
2/56
HPI44 years old F with PMH of migraine BIBEMS for
headache, which started the day before during the
eveningShe describes it as located to her R neck and occipital
area. On the next morning when she woke up the pain
was slighly worse so she took excidrin without
improvement .
-
7/31/2019 Hem Onc Presentation
3/56
HPIDescribed as throbbing, 7/10 intensity, radiated to her R
frontal area
The patient states that the headache this time was
different from her previous headaches related to her
Migraine
No aggravating/alleviating factors
-
7/31/2019 Hem Onc Presentation
4/56
HPIAssociated with nausea and 1 episode of NBNB
vomiting
No fever, photophobia, blurry vision, arm or leg
weakness, gait disturbances, slurred speech, dizziness or
facial asimmetry
VS: 98.9, 64, 15, 110/65
-
7/31/2019 Hem Onc Presentation
5/56
Social/Family HistoryLives with a sibling, in US x 12 years with no
recent travel
Works as a nanny caring for young childrenG1P1, denies miscarriages, denies OCP
Drinks occasionally , does not smoke or use drugs
Family Hx: noncontributory, no hx of DVT/bleeding or
clotting disorders in the family
-
7/31/2019 Hem Onc Presentation
6/56
Physical ExamAlert, oriented x3 fluent without disarthria or obviousdyhsphasiaCN: PERRL EOMI, intact visual field, no facial
paralysis or loss of sensation,uvula and tongue movesymmetrically about the midlineMotor : tone nl, strenght 5/5 all 4 ext decreased DTRs,planters downgoing
Sensory equal bilaterally to pinCoordination intactNeck suppleChest, CV, Abd exam unremarkable
-
7/31/2019 Hem Onc Presentation
7/56
ED meds Tylenol 650 mg x2
Metoclopramide 10 mg IVPB x1
Zantac 50 mg IVPB x 1 NS 1 L bolus
-
7/31/2019 Hem Onc Presentation
8/56
Labs11.3
35.3
1887.2137
3.8
102
28
7
0.7
89
Calcium: 8.9LDH 135
PT/PTT/INR : 10.9/1/26.8
-
7/31/2019 Hem Onc Presentation
9/56
Imaging CT brain: hyperdense R transverse sinus, concerning
for venous sinus thrombosis. No evidence of venousinfaction. No acute intracranial hemorrage, midlineshift, hydrocephalus or fracture
-
7/31/2019 Hem Onc Presentation
10/56
CT brain +
-
7/31/2019 Hem Onc Presentation
11/56
MRI / MRV w contrast
-
7/31/2019 Hem Onc Presentation
12/56
MRV reconstruction lack of contrast in the R
transverse sinus
-
7/31/2019 Hem Onc Presentation
13/56
Pt then admitted to the ICU for further management:
placed on neurochecks q2h and symptomatic
management, pending neurology consult
MRI C+/MRV: Confirms the R transverse sinusthrombosis . No evidence of parenchimal hemorrage,edema, or acute ischemic changes
-
7/31/2019 Hem Onc Presentation
14/56
Consults Neurosurgery : no neurosurgical intervention advised
Neurology: LMWH, keep good hydration and consult
hematology for possible hypercoagulable state Hematology: hypercoagulable w/u, peripheral flow
cytometry (CD55/CD59), AC
Neuro follow up: MRI/MRV rules out any other lesion,
especially AVM. AC warranted, 3-6 months vslifelong
-
7/31/2019 Hem Onc Presentation
15/56
Hypercoagulable workup AT III activity 104 Protrombin gene analysis: G20210A mutation not detected Protein S Ag: 134 Protein S activity: 67
Factor V Leiden (R506Q) Mutation: not detected Protein C Ag: 102 Protein C activity: 135 Haptoglobin 192 Beta 2 Microglobulin: 1.71 (VN
-
7/31/2019 Hem Onc Presentation
16/56
Hyercoagulable workup Factor XI activity: 99%
Factor VIII activity: 205% *
Factor IX activity: 34%* Lupus anticoagulant : detected
-
7/31/2019 Hem Onc Presentation
17/56
Discharge diagnosis Right transverse sinus thrombosis, secondary to
APLAS/ ?Elevated Factor VIII levels
Patient was told to f/u with Hem Onc clinic and that
she needed lifelong AC with coumadin (INR goal 2- 3)
-
7/31/2019 Hem Onc Presentation
18/56
Cerebral Venous Thrombosis (CVT)
-
7/31/2019 Hem Onc Presentation
19/56
Cerebral Venous Thrombosis (CVT)
Is the thrombosis of the cerebral veins and dural sinuses
Rare, represents less than 1% of all the strokes
-
7/31/2019 Hem Onc Presentation
20/56
Cerebral Venous Thrombosis (CVT) A prothrombotic risk factor or a direct cause is identified in
about 85% of the patients
Genetic predisposition (thrombophilia)
Acquired factors : Trauma, Infections (Sepsis,
Meningitis,Otitis, mastoidistis, sinusitis), LP, cancer,myeloproliferative diseases,Inflammatory diseases,Pregnancy, Nephrotic Syndrome, APS
Interestingly ,the prothrombin mutation was more than
twice as common in patients with CVT vs LE DVT andactivated protein C resistance, factor V Leiden, and proteinC deficiency were more common in patients with DVT(Wisokinska Wisokinsky at al Neurology 2008)
-
7/31/2019 Hem Onc Presentation
21/56
Cerebral Venous Thrombosis (CVT) Most common symptoms and signs: HA, focal or
generalized seizures, focal or generalized neurologicaldeficits, altered mental status, papilledema
Diagnosis is confirmed by MRI to visualize the thrombosedvessel and MRV to confirm the absence of flow in the vessel
-
7/31/2019 Hem Onc Presentation
22/56
Cerebral Venous Thrombosis (CVT) Although documented the tendency of venous infarcts to
become hemorrhagic (40%, Ferro, Canhao et al) evenbefore the AC treatment is started, there is indication to
treat patients with CVT with either UFH or LMWH, evenin patients with cerebral venous infarction and hemorragicconversion (Einhaupl, Bousser, de Bruijn et al)
Prognosis is good if appropriate treatment received early,
Risk factors for a bad outcome (13%) are male gender, age>37, AMS, coma, cerebral hemorrhage, cancer, thrombosisof deep cerebral venous system, CNS infection
-
7/31/2019 Hem Onc Presentation
23/56
Thrombophilia Is a genetically determined increased risk of venous
thrombosis or thromboembolism (VTE)
Multiple possible acquired predisposing risk factorscouple the effect of the genetic predisposition
-
7/31/2019 Hem Onc Presentation
24/56
Thrombophilia
-
7/31/2019 Hem Onc Presentation
25/56
Coagulation cascade
-
7/31/2019 Hem Onc Presentation
26/56
Coagulation Cascade
-
7/31/2019 Hem Onc Presentation
27/56
Coagulation Cascade
-
7/31/2019 Hem Onc Presentation
28/56
ThrombophiliaIn inherited thrombophilias, thrombosis is most often caused by impaired
neutralization of thrombin or failure to control the generation of thrombin
Seligsohn U and Lubetsky A. N Engl J Med 2001;344:1222-1231
-
7/31/2019 Hem Onc Presentation
29/56
Thrombophilia
Seligsohn U and Lubetsky A. N Engl J Med 2001;344:1222-1231
-
7/31/2019 Hem Onc Presentation
30/56
Thrombophilia
-
7/31/2019 Hem Onc Presentation
31/56
Thrombophilia
-
7/31/2019 Hem Onc Presentation
32/56
Factor V Leiden (FVL)
-
7/31/2019 Hem Onc Presentation
33/56
Factor V Leiden (FVL) >90% of hereditary APCR subjects have the same
abnormality, Factor V Leiden with a G1591A alterationcausing an Arg506Gln substitution
Deep and superficial venous thromboses are the mostcommon manifestations ; PE less frequent that insubjects with deficiencies in AT, prot C, prot S
Unusual (cerebral, hepatic, portal, mesenteric and
upper-extremity) venous thromboses reported
-
7/31/2019 Hem Onc Presentation
34/56
Prothrombin G20210A Substitution
-
7/31/2019 Hem Onc Presentation
35/56
Prothrombin G20210A Substitution Replacement of G byA at nt 20210 in the 3-
untranslated region of the prothrombin geneaugments translation and stability of prothrombinmRNA increased synthesis and secretion by theliver
Venous thrombosis (usual/unusual sites)
-
7/31/2019 Hem Onc Presentation
36/56
Hyperhomocysteinemia
Loscalzo J. N Engl J Med 2006;354:1629-1632
-
7/31/2019 Hem Onc Presentation
37/56
Hyperhomocysteinemia
-
7/31/2019 Hem Onc Presentation
38/56
Hyperhomocysteinemia The most common genetic cause of mild
hyperhomocysteinemia involves an MTHFR genepolymorphism ntC677T which causes a conservativereplacement of Ala222 by Val that results in a variantenzyme with reduced specific activity and increased
thermolability Suboptimal Folate, B6 or B12 Vitamin levels can contribute
to acquired mild to moderate hyperhomocysteinemia byproviding inadequate cofactor levels to support theenzymes that regulates homocysteine metabolism. Other
causes are renal failure, hypothiroidism, smoking, excessivecoffee consumption, IBD, psoriasis and RA
VTE, unusual sites venous thrombosis
Blood samples should be obtained in a fasting state, keptcold and centrifuged immediately
-
7/31/2019 Hem Onc Presentation
39/56
Protein C deficiency
-
7/31/2019 Hem Onc Presentation
40/56
Protein C deficiencyVitamin K dependant protein More than 150 mutations described
Deep and superficial vein thromboses the mostcommon clinical presentation (usual/unusual sites)
Immunoassays are used to distinguish type I defectsfrom type II
Liver disease or OCPs can lower or increaserespectively its level
A waiting period of at least 2 weeks afterdiscontinuation of AC therapy is required for a reliablediagnosis
-
7/31/2019 Hem Onc Presentation
41/56
Protein S deficiency
-
7/31/2019 Hem Onc Presentation
42/56
Protein S deficiency Vitamin K dependant protein Circulates as both a free protein (40%) and bound C4b-binding
protein (60%), which is part of the classic complement system
Only free Protein S can act as a cofactor to APC for the inhibition ofFactors Va and VIIIa
C4b is increased in acute phase reactions, causing free Protein Sto be decreased
DVT/PE/thrombosis at unusual sites
Levels are reduced during pregnancy, OCPs, HRT, oral AC
therapy, DIC, liver disease, nephrotic syndrome, inflammatorycondition, acute VTE
Assessment of total and free Protein S plus Protein S activityshould allow classification of patients in type I, II, or III
-
7/31/2019 Hem Onc Presentation
43/56
Antithrombin deficiency
-
7/31/2019 Hem Onc Presentation
44/56
Antithrombin deficiency
vitamin K-independent protein Prevalence: 1:2000-1:5000 persons 30% of heterozygotes develop a thrombosis by
30yrs, 65% by age 50yrs Homozygous deficiency is almost always
incompatible with life 60% will have recurrent thrombosis
Risk of thrombosis is particularly high in pregnancy Heparin prophylaxis recommended throughout
pregnancy and coumadin for 6 weeks postpartum
-
7/31/2019 Hem Onc Presentation
45/56
Antithrombin deficiencyAT Ag measurement and acitvity assays help
distinguish type I from type II defects
Levels affected by acute VTE, liver disease, DIC,
nephrotic syndrome, chemotherapy with asparaginase,and preeclampsia
-
7/31/2019 Hem Onc Presentation
46/56
Elevated Factor VIII Levels ?Genetic, no specific genetic abnormality described The mechanism by which increases the risk of
thrombosis are unknown (by diminishing the effect ofAPC?)
Levels can be elevated in pregnancy, increasedage/BMI, surgery, chronic inflammation, liver disease,hyperthyroidism , DM, exercise, acute VTE
Represents the most common prothrombotic riskfactor for CVT (Bugnicourt J, Russel B, J NeurolNeurosug Psychiatry 2007)
-
7/31/2019 Hem Onc Presentation
47/56
Elevated Factor VIII Levels
Studies done on ABO groups showed that there is anassociation between non-O groups and higher levels ofVWF/Factor VIII
Individuals with blood group O have 25-30% lowerVWF levels than non-O groups
In individuals with the FVL who have the AB genotype,the weak deactivation of FVIII thought to be mediated
by a lower catabolism of the VWF influenced by theAB alleles in combination with high levels of thisfactor are thought to result in an exponential increasein the risk of developingVTE (Morelli et al., 2005)
-
7/31/2019 Hem Onc Presentation
48/56
Anti Phospholipid (aPL) syndrome (APS)
Is a disorder in which vascular thrombosis orpregnancy complications attributable to placentalinsufficiency occur in patients with laboratoryevidence of antibodies directed against proteins thatbind to phospholipids
aPL Ab are defined as antibodies that recognizephospholipids, proteins that binds to phospholipids,
or inhibit phospholipid-dependant coagulationreactions
-
7/31/2019 Hem Onc Presentation
49/56
Anti Phospholipid (aPL) syndrome (APS)
Antigen targets: domain I ofb2 GPI, prothrombin,factor V, Protein C, Protein S, annexin A2, annexin A5,high and lw molecular weight kininogens, factorsVII/VIIa
Molecular mimicry between b2 GPI-related syntheticpeptides and structures within bacteria, viruses, andtetanus toxoid have been demostrated in expreimental
models
-
7/31/2019 Hem Onc Presentation
50/56
Anti Phospholipid syndrome (APS)
-
7/31/2019 Hem Onc Presentation
51/56
Anti Phospholipid syndrome (APS)Sidney Investigation Criteria for the diagnosis of APSo Clinical
one or more episodes of arterial, venous or small vessel thrombosis pregnancy morbidities attributable to placental insufficiency ,
including : three or more otherwise unexplained recurrentspontaneous miscarriages, before 10 weeks gestation. Also, one ormore fetal lossess after the 10 week of gestation, stillbirth, pretermlabor, placentar abruption, intrauterine growth restriction oroligohydramnios that are otherwise unexplained
o Laboratory aCL or anti-b2 GPI IgG or IgM in medium or high titer in2 or more
occasions at least 12 weeks apart Lupus anticoagulant in plasma on two or more occasions at least 12
weeks apart
Definite APS if at least one of the clinical criteria and one of thelaboratory criteria are met
-
7/31/2019 Hem Onc Presentation
52/56
Workup for suspected hypercoagulability
-
7/31/2019 Hem Onc Presentation
53/56
Seligsohn U and Lubetsky A. N Engl J Med 2001;344:1222-1231
-
7/31/2019 Hem Onc Presentation
54/56
-
7/31/2019 Hem Onc Presentation
55/56
Workup for suspected hypercoagulabilityPossible Indications for extension of Anticoagulant
Therapy Beyond 6 months*6-18 months: Elevated factor VIII level
Increased level of D-dimerActive cancerSevere venous insufficiencyIliofemoral venous thrombosis
Residual thrombosis detected by U/SPersistence of inciting cause
Indefinite: Life threatening eventCVT
Visceral vein thrombosisRecurrent event
Deficiencies of AT, Protein C, or Protein SCombined thrommbophiliasPresence of aPL Antibodies
* An extension of the therapy should be carefully evaluated and probably not applied inpatients with a great risk of bleeding, for example age >70 years, renal failure, or poorlycontrolled AC therapy
-
7/31/2019 Hem Onc Presentation
56/56
Some interestingarticles
Cerebral sinus vein thrombosis N Engl J Med 2005;352:1791-8. The "cord sign" in cerebral venous thrombosisassociated with high plasma levels of factor VIII.Giraldo EA, Petrinjac-Nenadic RNeurocrit Care. 2011 Aug;15(1):186-9.
J Neurol Neurosurg Psychiatry 2007;78:699-701 doi:10.1136/jnnp.2006.103465Cerebral venous thrombosis and plasma concentrations ofFactor VIII and von Willebrand factor: a case control studyJean-Marc Bugnicourt1, Bertrand Roussel2, Blaise Tramier3,Chantal Lamy1Olivier Godefroy1
ASH Education Program Bookasheducationbook.hematologylibrary.org doi:10.1182/asheducation-2005.1.462ASH Education Book January 1, 2005 vol. 2005 no. 1 462-468 Thrombosis and the Antiphospholipid Syndrome , Thomas Ortel
http://www.ncbi.nlm.nih.gov/pubmed?term=%22Giraldo%20EA%22[Author]http://www.ncbi.nlm.nih.gov/pubmed?term=%22Petrinjac-Nenadic%20R%22[Author]http://jnnp.bmj.com/search?author1=Jean-Marc+Bugnicourt&sortspec=date&submit=Submithttp://jnnp.bmj.com/search?author1=Bertrand+Roussel&sortspec=date&submit=Submithttp://jnnp.bmj.com/search?author1=Blaise+Tramier&sortspec=date&submit=Submithttp://jnnp.bmj.com/search?author1=Chantal+Lamy&sortspec=date&submit=Submithttp://jnnp.bmj.com/search?author1=Olivier+Godefroy&sortspec=date&submit=Submithttp://jnnp.bmj.com/search?author1=Olivier+Godefroy&sortspec=date&submit=Submithttp://jnnp.bmj.com/search?author1=Chantal+Lamy&sortspec=date&submit=Submithttp://jnnp.bmj.com/search?author1=Chantal+Lamy&sortspec=date&submit=Submithttp://jnnp.bmj.com/search?author1=Chantal+Lamy&sortspec=date&submit=Submithttp://jnnp.bmj.com/search?author1=Blaise+Tramier&sortspec=date&submit=Submithttp://jnnp.bmj.com/search?author1=Blaise+Tramier&sortspec=date&submit=Submithttp://jnnp.bmj.com/search?author1=Blaise+Tramier&sortspec=date&submit=Submithttp://jnnp.bmj.com/search?author1=Bertrand+Roussel&sortspec=date&submit=Submithttp://jnnp.bmj.com/search?author1=Jean-Marc+Bugnicourt&sortspec=date&submit=Submithttp://jnnp.bmj.com/search?author1=Jean-Marc+Bugnicourt&sortspec=date&submit=Submithttp://jnnp.bmj.com/search?author1=Jean-Marc+Bugnicourt&sortspec=date&submit=Submithttp://jnnp.bmj.com/search?author1=Jean-Marc+Bugnicourt&sortspec=date&submit=Submithttp://jnnp.bmj.com/search?author1=Jean-Marc+Bugnicourt&sortspec=date&submit=Submithttp://www.ncbi.nlm.nih.gov/pubmed?term=%22Petrinjac-Nenadic%20R%22[Author]http://www.ncbi.nlm.nih.gov/pubmed?term=%22Petrinjac-Nenadic%20R%22[Author]http://www.ncbi.nlm.nih.gov/pubmed?term=%22Petrinjac-Nenadic%20R%22[Author]http://www.ncbi.nlm.nih.gov/pubmed?term=%22Petrinjac-Nenadic%20R%22[Author]http://www.ncbi.nlm.nih.gov/pubmed?term=%22Petrinjac-Nenadic%20R%22[Author]http://www.ncbi.nlm.nih.gov/pubmed?term=%22Giraldo%20EA%22[Author]http://www.ncbi.nlm.nih.gov/pubmed?term=%22Giraldo%20EA%22[Author]http://www.ncbi.nlm.nih.gov/pubmed?term=%22Giraldo%20EA%22[Author]